PDF(Pubmed)
Abstract：
UNASSIGNED: This retrospective review documents the experience of ipratropium bromide use among pediatric patients with sialorrhea at our multidisciplinary sialorrhea clinic at Children\'s Hospital at London Health Sciences Centre (LHSC).
UNASSIGNED: A retrospective chart review of patients diagnosed with sialorrhea at our multidisciplinary clinic between January 2015 and June 2021 was completed. Data on patient demographics, comorbidities, clinical presentation, previous interventions, quality of life, and medication adverse side effects was collected. Drooling Frequency and Severity Scale (DFSS) scores were reviewed to compare sialorrhea management pre- and post-treatment with topical 0.03% ipratropium bromide nasal solution. A descriptive analysis and Wilcoxon signed rank tests were conducted to compare pre- versus post-treatment DFSS scores.
UNASSIGNED: A total of 12 patients presented for follow-up and were included in the final analysis. At the pre-treatment visit, the median DFSS score was 4 for frequency and 5 for severity. Post-treatment, median DFSS score was 3 for frequency and 4.5 for severity, (P = .020 and .129, respectively). Minimal adverse effects were encountered.
UNASSIGNED: Ipratropium bromide provided a statistically significant benefit for drooling frequency in the patients studied and may present an additional topical medical option for pediatric sialorrhea with limited adverse effects.
UNASSIGNED: A retrospective chart review of patients diagnosed with sialorrhea at our multidisciplinary clinic between January 2015 and June 2021 was completed. Data on patient demographics, comorbidities, clinical presentation, previous interventions, quality of life, and medication adverse side effects was collected. Drooling Frequency and Severity Scale (DFSS) scores were reviewed to compare sialorrhea management pre- and post-treatment with topical 0.03% ipratropium bromide nasal solution. A descriptive analysis and Wilcoxon signed rank tests were conducted to compare pre- versus post-treatment DFSS scores.
UNASSIGNED: A total of 12 patients presented for follow-up and were included in the final analysis. At the pre-treatment visit, the median DFSS score was 4 for frequency and 5 for severity. Post-treatment, median DFSS score was 3 for frequency and 4.5 for severity, (P = .020 and .129, respectively). Minimal adverse effects were encountered.
UNASSIGNED: Ipratropium bromide provided a statistically significant benefit for drooling frequency in the patients studied and may present an additional topical medical option for pediatric sialorrhea with limited adverse effects.
摘要：
■这项回顾性审查记录了在伦敦健康科学中心（LHSC）儿童医院的多学科鼻漏诊所中，小儿鼻漏患者使用异丙托溴铵的经验。
完成了2015年1月至2021年6月在我们的多学科诊所诊断为流涎的患者的回顾性图表回顾。患者人口统计数据，合并症,临床表现,以前的干预措施，生活质量,收集药物不良反应。对流口水频率和严重程度量表（DFSS）评分进行了审查，以比较局部使用0.03％异丙托溴铵鼻腔溶液治疗前后的流涎管理。进行描述性分析和Wilcoxon符号秩检验以比较治疗前与治疗后的DFSS评分。
■共有12名患者接受随访，并纳入最终分析。在治疗前的访问中，频率和严重程度的中位DFSS评分分别为4分和5分.后处理,中位DFSS评分频率为3，严重程度为4.5，（P分别为.020和.129）。副作用最小。
■异丙托溴铵对所研究患者的流口水频率提供了统计学上的显着益处，并且可能为小儿流涎提供了一种额外的局部医疗选择，不良反应有限。
完成了2015年1月至2021年6月在我们的多学科诊所诊断为流涎的患者的回顾性图表回顾。患者人口统计数据，合并症,临床表现,以前的干预措施，生活质量,收集药物不良反应。对流口水频率和严重程度量表（DFSS）评分进行了审查，以比较局部使用0.03％异丙托溴铵鼻腔溶液治疗前后的流涎管理。进行描述性分析和Wilcoxon符号秩检验以比较治疗前与治疗后的DFSS评分。
■共有12名患者接受随访，并纳入最终分析。在治疗前的访问中，频率和严重程度的中位DFSS评分分别为4分和5分.后处理,中位DFSS评分频率为3，严重程度为4.5，（P分别为.020和.129）。副作用最小。
■异丙托溴铵对所研究患者的流口水频率提供了统计学上的显着益处，并且可能为小儿流涎提供了一种额外的局部医疗选择，不良反应有限。
